Facial angiofibromas treated with topical rapamycin: An excellent choice with fast response

Dermatology Online Journal

Volumn 18, Issue 1, 2012, Pages

  Truchuelo, Teresa ^a   Díaz Ley, Blanca ^a   Ríos, Luis ^a   Alcántara, Javier ^a   Jaén, Pedro ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC;

CARBON DIOXIDE LASER; CASE REPORT; CHEEK; CHILD; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL ANGIOFIBROMA; FEMALE; HEMANGIOFIBROMA; HUMAN; HYPOPIGMENTATION; LETTER; PAPULE; PHYSICAL EXAMINATION; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; ARTICLE; FACE TUMOR; SKIN TUMOR;

ANGIOFIBROMA; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; FACIAL NEOPLASMS; FEMALE; HUMANS; SIROLIMUS; SKIN NEOPLASMS; TUBEROUS SCLEROSIS;

EID: 84856546231     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (16)

1. Schwartz, R.A., Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57(2):189-202. [PubMed]
2. Fernández Guarino M., Boixeda P, Anaya MJ, Beldar P, Jaén P. Esclerosis tuberosa. Hallazgos clínicos en 67 pacientes. Actas Dermosifiliogr 2009;100:597-602. [PubMed]
3. Kaufman McNamara E, Curtis AR, Fleischer Jr AB. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatolog Treat 2010: 1-3. [PubMed]
4. Hofbauer, GF., Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, Serra AL. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008;159(2):473-5. [PubMed]
5. Haemel, AK., O'Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010;146(7):715-8. [PubMed]
6. DeKlotz C., Ogram A, Singh S, Dronavalli S, MacGregor J. Dramatic Improvement of Facial Angiofibromas in Tuberous Sclerosis With Topical Rapamycin: Optimizing a Treatment Protocol. Arch Dermatol. 2011;147:1116-1117. [PubMed]
7. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med2008;358(2):140-51. [PubMed]
8. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59(3):490-8. [PubMed]
9. Peces R, Peces C, Cuesta-López E, Pérez-Dueñas V, Vega-Cabrera C, Azorín S, Selgas R. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrol Dial Transplant 2010;25(11):3787-91. [PubMed]
10. Tarasewicz, A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 2009;41(9): 3677-82. [PubMed]
11. Micozkadioglu H, Koc Z, Ozelsancak R, Yildiz I. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient. Ren Fail 2010;32(10): 1233-6. [PubMed]
12. Rauktys R, Koc Z, Ozelsancak R, Yildiz I. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 2008; 8:1. [PubMed]
13. Valerón-Almazán P, Vitiello M, Abuchar A, Kerdel FA. Topical Rapamycin Solution to Treat Multiple Facial Angiofibromas in a Patient With Tuberous Sclerosis. Actas Dermosifiliogr. 2011 Aug 20. [PubMed]
14. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005;152(4): 758-64. [PubMed]
15. Soria A, Agbo-Godeau S, Taïeb A, Francès C. Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases. Dermatology 2009;218(1): 22-5. [PubMed]
16. Baba M, Furihata M, Hong SB, Tessarollo L, Haines D, Southon E. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008:16;100(2): 140-154. [PubMed]